Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.3252W HIGH $2.85
Volume
187.75 K
Value Traded
2.71 M
Short % Float
18.42%
+0.69%Week
-29.27%1 Month
-26.02%3 Month
-20.33%6 Month
-99.93%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
256.87 M
EPS (TTM)
-0.18
P/E Ratio
-
Ent. Value
127.52 M
Total Shares
174.27 M
Float Shares
164.32 M
Insiders
5.71%
Institutions
97.50%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PALI Catalyst Timeline
Dated clinical, regulatory and corporate events for Palisade Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Palisade Bio, Inc.
901Total events
14Upcoming
123Tier-1 (high impact)
2010 to 2028Coverage
Upcoming catalysts 2
Event history 50
●R&D DayPALI-2108Presentation
Palisade Bio to present PALI-2108 program update at Stifel 2026 Virtual Immunology and Inflammation Forum
ulcerative colitis and Crohn's diseasesource ↗
▲Trial Authorization (CTA / IND)PALI-2108Ex-US Regulatory
Health Canada clears CTA for ASCENTRA-UC global Phase 2 study of PALI-2108
moderately to severely active ulcerative colitissource ↗
▲IND ClearancePALI-2108IND
FDA clears IND for PALI-2108 in moderate to severe Crohn's disease
Crohn's diseasesource ↗
▲Trial InitiationPALI-2108Trial
Initiation of Phase 2 ASCENTRA-CD trial in Crohn's disease enabled by IND clearance
Crohn's diseasesource ↗
▲IND ClearancePALI-2108IND
FDA clearance of IND for PALI-2108 for Phase 2 ASCENTRA-UC trial
ulcerative colitissource ↗
●Oral PresentationPALI-2108Presentation
Showcased PALI-2108's targeted PDE4 inhibition strategy in fibrostenotic Crohn's disease at 4th Annual Precision Medicine in IBD Summit
Crohn's diseasesource ↗
▲Milestone PaymentCorporate
Recognized license revenue of $0.5 million related to achievement of a milestone under co-development and distribution agreement with Newsoara
●Oral PresentationPALI-2108Presentation
Presentation at NYAS symposium on PALI-2108 for fibrostenotic Crohn’s disease
Fibrostenotic Crohn’s Diseasesource ↗
◆Oral PresentationPresentation
Palisade Bio to present at Jefferies Global Healthcare Conference
▲Full ResultsPALI-2108Clinical Data
Phase 1b FSCD cohort results reported
fibrostenotic Crohn's diseasesource ↗
▲Trial CompletionPALI-2108Trial
Completed Phase 1a/b for PALI-2108
ulcerative colitis and fibrostenotic Crohn's diseasesource ↗
▲Topline ReadoutPALI-2108Clinical Data
Reported positive data from Phase 1b FSCD cohort
fibrostenotic Crohn's diseasesource ↗
●Poster PresentationPALI-2108Presentation
Poster presentation at Digestive Disease Week 2026
ulcerative colitissource ↗
●Oral PresentationPALI-2108Presentation
Phase 1 translational findings presented at DDW 2026
ulcerative colitissource ↗
◆Oral PresentationPresentation
Palisade Bio to present at Needham & Co. 25th Annual Healthcare Conference
◆First Patient DosedPALI-2108Trial
Enrollment of first patient for Phase 2 ASCENTRA-UC trial expected
ulcerative colitissource ↗
◆IND SubmissionPALI-2108IND
IND submission for Phase 2 UC trial expected in 2Q 2026
ulcerative colitissource ↗
◆Oral PresentationPALI-2108Presentation
Presentation of topline data at 4th Annual Precision Medicine in IBD Summit
fibrostenotic Crohn's diseasesource ↗
▲Topline ReadoutPALI-2108Clinical Data
Positive topline data from Phase 1b study of PALI-2108 in fibrostenotic Crohn's disease
fibrostenotic Crohn's diseasesource ↗
●Oral PresentationPresentation
Palisade Bio to hold one-on-one investor meetings at Leerink Partners 2026 Global Healthcare Conference
●Oral PresentationPresentation
Palisade Bio to present at TD Cowen 46th Annual Health Care Conference
◆Oral PresentationPresentation
Palisade Bio to present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
▲Poster PresentationPALI-2108Presentation
Poster presentation of Phase 1b translational data at ECCO 2026
ulcerative colitissource ↗
▲Topline ReadoutPALI-2108Clinical Data
Phase 1b cohort results: 100% clinical response in UC cohort
ulcerative colitissource ↗
◆Poster PresentationPALI-2108Presentation
Poster presentation at ECCO Congress 2026
Ulcerative Colitissource ↗
▲Management ChangeCorporate
Appointment of Bram Verstockt, MD, PhD to Clinical Advisory Board
●Oral PresentationPresentation
Palisade Bio to participate in virtual fireside chat at Piper Sandler Virtual Novel Targets in Immunology Symposium
◆Poster PresentationPALI-2108Presentation
Poster presentation at Crohn's & Colitis Congress 2026
Ulcerative Colitissource ↗
▲Equity OfferingCorporate
Crohn's & Colitis Foundation IBD Ventures program approves up to $500,000 equity investment in Palisade
▲Partnership / LicensePALI-2108Corporate
Crohn's & Colitis Foundation IBD Ventures approves strategic equity investment of up to $500,000
fibrostenotic Crohn's disease and moderate to severe ulcerative colitissource ↗
◆Topline ReadoutPALI-2108Clinical Data
Topline data anticipated in Q1 2026
fibrostenotic Crohn’s disease (FSCD)source ↗
▲Patent GrantedPALI-2108IP / Competition
Japan Patent Office granted composition-of-matter patent for PALI-2108
◆Oral PresentationPresentation
Palisade Bio to present at Piper Sandler 37th Annual Healthcare Conference
●Management ChangeCorporate
Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development
●Management ChangeCorporate
Appointment of Sharon Skare as VP, Global Head of Clinical Operations
▲Topline ReadoutPALI-2108Clinical Data
Positive data reported from Phase 1a/1b study of PALI-2108 for UC
ulcerative colitissource ↗
Past FDA Catalysts and PDUFA Decisions
How PALI actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | PALI-2108 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D33 / 100
Pipeline Score
$84M
Pipeline Value
Overvalued
Valuation Signal
2
Drugs Scored
0.3x
rNPV / MCap
Top 60%
Micro Cap(rank 395 of 658)
Percentile Rank
Palisade Bio, Inc. faces pipeline headwinds (33/100), with $334M risk-adjusted pipeline value, led by PALI-2108 in Fibrostenotic Crohn's Disease (Phase 1).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PALI-2108 Small moleculeNCT06663605 | Ulcerative Colitis (UC) | Phase 2 | COMPLETED | 293 | Aug 7, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every PALI program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PALI-2108 | fibrostenotic Crohn’s disease | 2026-06-09 | positive results in a Phase 1a and two Phase 1b clinical trialsRead More | Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences SymposiumRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Finley John DavidDirector, Officer (CEO CFO) | Option | 3,227,384 3,356,672 held | $0.00 | 10/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PALI
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SOLEUS CAPITAL MANAGEMENT, L.P. | 0.9 % | 27.30 M | 13.06 M |
PALI Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PALI ranks across every disease it competes in
Competitive Position is a premium feature
See how PALI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPALI News
PALIPalisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026
Palisade Bio will present findings on PALI-2108 at UEG Week 2026, highlighting its early clinical activity in ulcerative colitis and fibrostenotic Crohn's disease. The presentations will showcase favorable safety, tolerability, and a new biomarker for predicting treatment response. PALI-2108 is advancing into Phase 2 trials for inflammatory bowel disease.
Read more →PALI▼ -5.3%on this newsshared move
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Palisade Bio has received Health Canada clearance for its Clinical Trial Application for ASCENTRA-UC, a Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. This approval allows the company to expand its clinical trial activities in Canada, supporting patient enrollment. Primary efficacy results are anticipated in the second half of 2027.
Read more →PALIPalisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD
Palisade Bio has received FDA clearance for its IND application for PALI-2108, enabling the start of the Phase 2 ASCENTRA-CD trial in patients with moderate to severe Crohn's disease. The trial will evaluate the drug's efficacy, safety, and pharmacokinetics in approximately 60 patients, with primary results expected by Q1 2028. PALI-2108 aims to provide a targeted treatment option for patients experiencing inadequate responses to existing therapies.
Read more →PALI▲ +6.3%on this newsshared move
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Palisade Bio, a clinical-stage biopharmaceutical company, will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026. CEO JD Finley and CMO Mitchell Jones will discuss the PALI-2108 clinical development program, focusing on ulcerative colitis and Crohn's disease. The event will also include opportunities for one-on-one meetings with investors.
Read more →PALIPalisade Bio to Participate in Upcoming Investor Conferences
Palisade Bio, Inc. announced its participation in three upcoming healthcare investor conferences in September 2026. The conferences include the Wells Fargo 2026 Healthcare Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the H.C. Wainwright 28th Annual Global Investment Conference. The company is also advancing its lead candidate, PALI-2108, into Phase 2 clinical trials for inflammatory bowel disease.
Read more →PALIPalisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development
Palisade Bio reported its second quarter 2026 financial results, highlighting the advancement of PALI-2108 into Phase 2 trials for ulcerative colitis and Crohn's disease. The company expects to enroll the first patient in the ASCENTRA-UC trial in the latter half of 2026, with primary efficacy results anticipated in 2027. Despite a significant net loss, Palisade's strong financial position supports its clinical development plans.
Read more →PALIPalisade Bio to Participate in the Leerink Partners Therapeutics Forum
Palisade Bio, Inc. will participate in the Leerink Partners Therapeutics Forum on July 14-15, 2026, in Boston. CEO JD Finley and CMO Dr. Mitchell Jones will engage in one-on-one meetings with investors to discuss the clinical development of PALI-2108, a PDE4 inhibitor prodrug. The company is advancing towards Phase 2 studies for inflammatory bowel diseases.
Read more →PALI▲ +18%on this news
Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis
Palisade Bio has received FDA clearance for its IND application for PALI-2108, allowing the initiation of the ASCENTRA-UC Phase 2 trial in ulcerative colitis. The trial will enroll up to 204 patients across North America and Europe, with results expected in late 2027. This marks a significant milestone for the company's inflammatory bowel disease portfolio.
Read more →PALI▲ +6%on this news
Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors
Palisade Bio has appointed Robert Baltera and Jordan Zwick to its Board of Directors, enhancing its leadership team with extensive biopharmaceutical expertise. The company is progressing PALI-2108, a PDE4 inhibitor prodrug, toward Phase 2 clinical studies following encouraging results from earlier trials. This strategic move aims to strengthen the company's growth and development in addressing inflammatory bowel diseases.
Read more →PALIPalisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium
Palisade Bio will present on PALI-2108, a PDE4 inhibitor prodrug, at the NYAS symposium. The presentation will address the unmet needs in treating fibrostenotic Crohn's disease and discuss preclinical findings supporting the drug's potential. PALI-2108 has shown promise in early clinical trials, and the company is moving towards Phase 2 studies.
Read more →PALIPalisade Bio to Participate in the Jefferies Global Healthcare Conference
Palisade Bio, Inc. is set to present at the Jefferies Global Healthcare Conference from June 2-4, 2026, with a scheduled presentation on June 4. CEO JD Finley and CMO Dr. Mitchell Jones will lead the discussion, covering the company's innovative oral PDE4 inhibitor, PALI-2108, which shows promise in treating inflammatory and fibrotic diseases. The firm is moving forward to Phase 2 studies after positive outcomes in earlier clinical trials for ulcerative colitis and Crohn’s disease. Management will also hold one-on-one meetings with investors during the conference.
Read more →PALIPalisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108
Palisade Bio reported its first quarter 2026 financial results, highlighting the progress of its lead program, PALI-2108, a PDE4 inhibitor prodrug for inflammatory bowel disease. The company plans to initiate Phase 2 trials for ulcerative colitis and Crohn's disease in 2026, supported by a strong financial position. Recent data indicate sustained efficacy and safety of PALI-2108, reinforcing its potential as a treatment option.
Read more →PALI▼ -7.5%on this news
Palisade Bio Reports Additional Phase 1a/b Data Demonstrating Colon-Targeted Exposure and Sustained IC90 Coverage Supporting Once-Daily Dosing in Ulcerative Colitis
Palisade Bio presented additional Phase 1a/b data for PALI-2108, highlighting its potential as a once-daily oral therapy for ulcerative colitis. The findings indicate sustained active metabolite exposure above the IC90 threshold, supporting continuous target inhibition. The data also show significant improvements in clinical and histologic outcomes, reinforcing the drug's localized pharmacologic activity.
Read more →PALIPalisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio announced that its lead program, PALI-2108, will be presented at Digestive Disease Week 2026. The poster presentation will showcase data on the drug's effectiveness in treating ulcerative colitis. The event will take place in Chicago from May 2-5, 2026, where the company will engage with experts and investors.
Read more →PALIPalisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference
Palisade Bio, Inc. will present at the Needham & Co. 25th Annual Healthcare Conference on April 16, 2026. CEO JD Finley and CMO Dr. Mitchell Jones will discuss the company's advancements in oral PDE4 inhibitor prodrugs. The presentation will be accessible via webcast, and management will hold one-on-one meetings with investors.
Read more →PALI▼ -11%on this news
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease
Palisade Bio reported positive topline results from its Phase 1b study of PALI-2108 in patients with fibrostenotic Crohn's disease. The study demonstrated favorable safety and tolerability, with no serious adverse events. Notably, 40% of participants achieved endoscopic response and remission, alongside significant reductions in inflammatory biomarkers. The company plans to advance PALI-2108 into a Phase 2 trial targeting moderate to severe Crohn's disease.
Read more →PALIPalisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio, Inc. announced its participation in two investor conferences in March 2026, where management will present and hold meetings. The company is advancing its lead program, PALI-2108, which has shown a 100% clinical response in a Phase 1b trial for ulcerative colitis. Palisade is preparing for a Phase 2 study to further evaluate the drug's efficacy and safety.
Read more →About Palisade Bio, Inc.
Headquarters7750 EL CAMINO REAL, SUITE 5200, CARLSBAD, CA, 92009
BIOPHARMAWATCH ELITE PLUS
Trade the next PALI catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime